With the US suspension of Johnson & Johnson’s COVID-19 vaccine extended to two weeks, authorities resumed shots in a manner determined by European regulators, with warnings of “very rare” risks. I am considering whether to do it.
New guidance is expected late Friday after a government advisory board has examined the possibility of a link between J & J injections and a small number of vaccinated people who have developed a very rare blood clot.
The Centers for Disease Control and Prevention balances how high the risk really is and the need to vaccinate millions of people against the virus that infects tens of thousands of Americans each day. I’m looking for an advisor to help me decide.
“We appreciate the importance of acting swiftly,” said Dr. Rochelle Warrensky, director of the CDC, based on his advice. She wanted “risk and reward recommendations” for using J & J’s single-dose vaccine.
European regulators earlier this week allowed J & J’s shots to roll out after concluding that these benefits outweigh what appears to be a very rare risk, and many U.S. health experts agree. To do. However, one consideration for the CDC panel is that healthy young adults who are less likely to suffer from severe COVID-19 should be vaccinated with another vaccine because rare blood clots have been reported in people under the age of 60. Is it okay?
Naolbaseev, a vaccine expert at the Johns Hopkins Bloomberg School of Public Health, who watches over Friday’s debate, said:
The problem is an abnormal location, such as a vein that drains blood from the brain, or a strange type of blood clot that forms a blood clot in a patient with abnormally low platelet levels. The CDC and the Food and Drug Administration first found six people who developed such blood clots 1-3 weeks after J & J vaccination, one of whom died. The investigation then spread as the government received what it called a “handful” of additional blood clot reports, including death, which state officials said were being investigated in Oregon.
The haystack needle report warned that European regulators had already found a similar rare blood clot among the recipients of another COVID-19 vaccine from AstraZeneca. The shots of AstraZeneca and J & J are not the same, but they are made with the same technology.
Copyright 2021 AP communication. all rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
U.S. Health Commission reviews J & J vaccine to suspend on rare blood clots
Source link U.S. Health Commission reviews J & J vaccine to suspend on rare blood clots